Human Albumin Octapharma

Human Albumin Octapharma is a sterile solution for injection containing human serum albumin as the active ingredient. It is supplied in a standard concentration (e.g., 20% w/v) and is marketed in the European Union as a prescription plasma volume expander. The product is used intravenously to restore plasma oncotic pressure and support circulatory volume in various clinical situations, including trauma, surgery, and severe burns, or other acute conditions.

Human Albumin Octapharma is indicated for clinical situations where plasma volume expansion or albumin replacement is required.

- Treatment of hypovolemia due to hemorrhage, trauma, or surgery. - Management of hypoalbuminemia associated with liver disease, nephrotic syndrome, or malnutrition. - Volume replacement in patients with extensive burns. - Support during major surgical procedures to maintain oncotic pressure. - Adjunct therapy for plasma exchange or apheresis procedures.

Adverse reactions to Human Albumin Octapharma are generally related to the infusion process or to immunologic responses, and they can range from mild, transient symptoms to potentially life‑threatening events.

Common: - Mild fever, chills, or rigors occurring during or shortly after infusion. - Transient changes in blood pressure, such as mild hypotension or hypertension. - Headache, dizziness, or a feeling of light‑headedness. - Nausea, vomiting, or abdominal discomfort.

Serious: - Anaphylactic or severe allergic reaction, including urticaria, bronchospasm, or angioedema. - Acute hemolysis, renal impairment, or sudden rise in serum creatinine. - Volume overload leading to pulmonary edema, congestive heart failure, or respiratory distress.

Before administering Human Albumin Octapharma, clinicians should evaluate patient history and monitor specific clinical parameters to minimize risk.

- Assess for known hypersensitivity to human albumin or any component of the formulation. - Evaluate volume status; avoid use in patients with uncontrolled heart failure or severe renal impairment. - Monitor vital signs and fluid balance during and after infusion. - Use caution in patients with a history of thromboembolic events or coagulopathy. - Adjust dose in patients with severe hypoalbuminemia or altered plasma protein binding. - Consider infection control measures as the product is derived from human plasma.

Human Albumin Octapharma may interact with other intravenous therapies or medications that affect fluid balance, coagulation, or immune response.

Avoid: - Concurrent administration with other colloid solutions (e.g., hydroxyethyl starch) that may increase risk of volume overload. - Simultaneous infusion of blood products containing incompatible antibodies.

Use with caution: - Diuretics, as they may exacerbate intravascular volume shifts. - Anticoagulants or antiplatelet agents, due to potential additive effects on bleeding risk. - Vasopressors, because changes in plasma volume can alter drug responsiveness. - Immunosuppressive agents, which may mask signs of an allergic reaction.